Bio Pharma Dive

JANUARY 18, 2024

The company said it has secured agreement from labor representatives in Germany for job cuts that will shed “many managerial employees.

310

310

AuroBlog - Aurous Healthcare Clinical Trials blog

JANUARY 18, 2024

Conventional wisdom would have us believe the journey to a long and healthy life begins with 10,000 steps. Each and every day. For those living a more sedentary lifestyle, it’s a goal that can take some effort to maintain. We’ve also known for some time it’s also almost certainly wrong.

Scientist 233

Scientist Clinical Trials Clinical Trials Trials 233

Bio Pharma Dive

JANUARY 18, 2024

Called Advanced Medicine Partners, the new company will offer specialized cell and gene therapy manufacturing services to biotech and pharma clients.

Gene Therapy 290

Gene Therapy Manufacturing Gene Medicine 290

Pharmaceutical Technology

JANUARY 18, 2024

The endocannabinoid inhibitor SYT-510 will be investigated in healthy patients to assess its safety, tolerability, and pharmacokinetics.

214

214

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Medicine

AuroBlog - Aurous Healthcare Clinical Trials blog

JANUARY 18, 2024

Even as the central government is expected to present its interim budget for 2024-25 in less than three weeks, the Medical Technology Association of India (MTaI) has urged the Union Finance Ministry to reduce the customs duty on certain devices. “India’s current tariff duty structure on medical device imports is very high.

Clinical Trials 188

Clinical Trials Clinical Trials Clinical Research Trials 188

Bio Pharma Dive

JANUARY 18, 2024

The biotech will receive $500 million upon FDA approval of its rare disease drug acoramidis after selling 5% sales royalties to two investment firms.

FDA Approval 182

FDA Approval Drugs Sales 182

Bio Pharma Dive

JANUARY 18, 2024

The $50 million fund, called Mirae Asset Capital Life Science, will back biotechnology companies from seed to Series C rounds.

Life Science 182

Life Science 182

Pharma Times

JANUARY 18, 2024

Green light concerns generalised myasthenia gravis therapy

132

132

Pharmaceutical Technology

JANUARY 18, 2024

The AI Governance Alliance has called for stronger collaboration to create a framework for AI, as industry leaders gather in Davos.

130

130

XTalks

JANUARY 18, 2024

Affecting millions of people worldwide, autoimmune diseases present a complex and often debilitating set of challenges for patients. To that end, the quest for innovative treatments has led to the convergence of technology, research and patient-centric care. Over 80 distinct autoimmune disorders exist, with the most prevalent ones being multiple sclerosis, irritable bowel syndrome (IBS), lupus, type 1 diabetes, psoriasis and rheumatoid arthritis.

Clinical Trials 124

Clinical Trials Clinical Trials Trials Life Science 124

Advertisement

Clinical Supply

Pharmaceutical Technology

JANUARY 18, 2024

Expected to close on 22 January 2024, the German biotech’s offering follows the $1.7bn-topping deal with Moderna struck in late 2023.

130

130

Fierce Pharma

JANUARY 18, 2024

Six months after England’s National Institute for Health and Care Excellence (NICE) spurned Pfizer’s breast cancer treatment Talzenna (talazoparib) because it was not cost effective, the agency has | Six months after England’s National Institute for Health and Care Excellence spurned Pfizer’s breast cancer treatment Talzenna because it was not cost effective, the agency has reversed course following the company’s offer to slash the price.

Drugs 122

Drugs 122

Pharmaceutical Technology

JANUARY 18, 2024

Windtree and Lee's Pharmaceutical signed an agreement for istaroxime to treat acute heart failure and cardiogenic shock in Greater China.

130

130

pharmaphorum

JANUARY 18, 2024

This page explores the significant impact of artificial intelligence (AI) on the advancement of gene therapy development within the biopharmaceutical field.

Gene Therapy 120

Gene Therapy Gene Development 120

Advertisement

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

Clinical Trials

Pharmaceutical Technology

JANUARY 18, 2024

Xenetic has entered agreements with the University of Virginia (UVA) in the US to advance the systemic DNase programme.

130

130

Fierce Pharma

JANUARY 18, 2024

In its efforts to probe high U.S. drug prices, the Senate health committee has already heard from the heads of Moderna, Eli Lilly, Novo Nordisk and Sanofi. | The Senate Committee on Health, Education, Labor, and Pensions will vote on issuing subpoenas at the end of the month after the Johnson & Johnson and Merck CEOs refused to testify at an upcoming hearing.

Drugs 119

Drugs 119

Pharmaceutical Technology

JANUARY 18, 2024

Ratio Therapeutics has secured $50m in a Series B financing round, a significant move aimed at advancing radiotherapies for cancer treatment.

130

130

Pharma Times

JANUARY 18, 2024

Company is focused on endocannabinoid system treatments

117

117

Advertisement

Clinical Supply

Pharmaceutical Technology

JANUARY 18, 2024

Sun Pharma has signed a definitive merger agreement for the acquisition of all outstanding shares of Taro Pharmaceutical for $347.73m.

130

130

pharmaphorum

JANUARY 18, 2024

Medtech company DermaSensor gets FDA approval for a handheld device, powered by AI, that can be used to detect skin cancer at the point of care

FDA Approval 116

FDA Approval 116

Antidote

JANUARY 18, 2024

Antidote’s mission is to connect patients with medical research so medical breakthroughs can take place. A key part of our strategy is partnering with nonprofits and patient advocacy groups. We provide our clinical trial matching technology, Antidote Match, at no cost to these organizations, to help patients and caregivers discover new research opportunities and connect to clinical trials quickly and easily.

Clinical Trials 105

Clinical Trials Clinical Trials Trials Research 105

pharmaphorum

JANUARY 18, 2024

How post-fracture care programmes such as fracture liaison services can bridge the treatment gap for osteoporosis Mike.

115

115

Advertisement

This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.

Clinical Trials

XTalks

JANUARY 18, 2024

This episode of the Xtalks Food Podcast features an interview with with Eric Taipale, CTO of Sentera, a global technology leader for in-season data, analytics and insights for growers. Taipale discussed how Sentera’s technology specifically caters to the needs of growers and the agricultural community. He shared the benefits that generative AI provides to agriculture and the role that synthetic data generation has in accelerating technology adoption for the food industry.

Development 105

Development 105

pharmaphorum

JANUARY 18, 2024

AI-powered patient risk assessment company C2-Ai and the Sickle Cell Society have won an NHS contest to find solutions that can tackle health inequality

115

115

Pharmaceutical Commerce

JANUARY 18, 2024

In an interview with Pharma Commerce editor Nicholas Saraceno, Bill Roth, General Manager, Managing Partner, Blue Fin Group, discusses changes that will come with the pharma giant's new platform.

Sales 105

Sales Drugs 105

pharmaphorum

JANUARY 18, 2024

Pfizer’s PARP inhibitor Talzenna has become the first targeted treatment for HER2-negative locally advanced or metastatic breast cancer with BRCA1/2 mutations to be recommended by NICE for routine NHS use.

111

111

Advertisement

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

Clinical Research

Fierce Pharma

JANUARY 18, 2024

Roche's TIGIT antibody has posted a positive phase 3 result that probably won't lead anywhere. In a win for Daiichi Sankyo, a U.S. agency has invalidated a Seagen patent. | Roche's TIGIT antibody has posted a positive phase 3 result that probably won't lead anywhere. In a win for Daiichi Sankyo, a U.S. agency has invalidated a Seagen patent.

Antibody 104

Antibody Drugs 104

pharmaphorum

JANUARY 18, 2024

India’s Sun Pharma has signed an agreement to take full control of Israeli generic drugmaker Taro Pharmaceutical Industries, taking it into private hands.

110

110

Fierce Pharma

JANUARY 18, 2024

It took 17 years for Sun Pharmaceutical and Taro Pharmaceutical to finally tie the knot. | It took 17 years for Sun Pharmaceutical and Taro Pharmaceutical to finally tie the knot. On Thursday, the companies revealed their long-awaited merger, with Sun of Mumbai, India, agreeing to purchase outstanding shares in the Israeli drugmaker for $43 each. The deal nets out to $348 million for a 48% premium on Taro's share price of $29.

98

98

pharmaphorum

JANUARY 18, 2024

pharmaphorum editor-in-chief Jonah Comstock is back from San Francisco, where he attended the annual JP Morgan Healthcare Conference. In today’s podcast episode, guest host Eloise McLennan interviews him about what he saw and heard at the show.

109

109

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Clinical Trials